{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient data values to calculate coefficient of variation.","groupId":"OG000","spread":"NA","value":"318"},{"groupId":"OG001","spread":"60.2","value":"347"},{"groupId":"OG002","spread":"37.8","value":"1204"},{"groupId":"OG003","spread":"54.3","value":"1493"},{"groupId":"OG004","spread":"100.8","value":"2080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Day -1/Day 1"},{"categories":[{"measurements":[{"comment":"Insufficient data values to calculate coefficient of variation.","groupId":"OG000","spread":"NA","value":"179"},{"groupId":"OG001","spread":"100.7","value":"282"},{"groupId":"OG002","spread":"39.2","value":"1016"},{"groupId":"OG003","spread":"45.0","value":"1351"},{"groupId":"OG004","spread":"93.5","value":"1900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Plasma CC-223 was measured using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part A: CC-223 7.5 mg"},{"description":"Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part A: CC-223 15 mg"},{"description":"Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part A: CC-223 30 mg"},{"description":"Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part A: CC-223 45 mg"},{"description":"Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part A: CC-223 60 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with available pharmacokinetic data in Part A.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day -1: pre-dose, 0.5, 1, 1.5, 3, 5, 8, 24 and 48 hours post-dose and Day 15: pre-dose, 0.5, 1, 1.5, 3, 5, and 8 hours post-dose","title":"Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223","type":"PRIMARY","unitOfMeasure":"ng*h/mL"}